Recon: Lilly, AC Immune Partner on Alzheimer's Treatment; FDA R...

12/12/18

Recon: Lilly, AC Immune Partner on Alzheimer's Treatment; FDA Rejects Mallinckrodt's Abuse-Deterrent Opioid  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. FDA declines to approve Mallinckrodt's ...

[more]